About tRNA wybutosine-synthesizing protein 3 homolog
tRNA wybutosine-synthesizing protein 3 homolog (TYW3) is a protein
from Homo sapiens identified by UniProt accession
Q6IPR3, 259 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | tRNA wybutosine-synthesizing protein 3 homolog |
|---|
| UniProt accession | Q6IPR3 |
|---|
| Gene | TYW3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 259 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (16)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.26
- heel bone mineral density · score 0.25
- blood protein measurement · score 0.21
- protein measurement · score 0.17
- resistin measurement · score 0.15
- amyotrophic lateral sclerosis · score 0.10
- adolescent idiopathic scoliosis · score 0.08
- hepatocellular carcinoma · score 0.02
- axial length measurement · score 0.01
- Amyotrophic lateral sclerosis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6IPR3-F1 | alphafold | PREDICTED | 80.36 | — |
Amino-acid sequence (259 residues)
MDRSAEFRKW KAQCLSKADL SRKGSVDEDV VELVQFLNMR DQFFTTSSCA GRILLLDRGI NGFEVQKQNC CWLLVTHKLC VKDDVIVALK KANGDATLKF EPFVLHVQCR QLQDAQILHS MAIDSGFRNS GITVGKRGKT MLAVRSTHGL EVPLSHKGKL MVTEEYIDFL LNVANQKMEE NKKRIERFYN CLQHALERET MTNLHPKIKE KNNSSYIHKK KRNPEKTRAQ CITKESDEEL ENDDDDDLGI NVTIFPEDY
Explore tRNA wybutosine-synthesizing protein 3 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets